Celldex Therapeutics Ownership | Who Owns Celldex Therapeutics?


OverviewForecastRevenueFinancialsChart

Celldex Therapeutics Ownership Summary


Celldex Therapeutics is owned by 109.55% institutional investors, 0.27% insiders. Wellington management group llp is the largest institutional shareholder, holding 12.87% of CLDX shares. Vanguard Health Care Inv is the top mutual fund, with 5.45% of its assets in Celldex Therapeutics shares.

CLDX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockCelldex Therapeutics109.55%0.27%-9.82%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Wellington management group llp8.56M12.87%$271.54M
Kynam capital management, lp5.84M8.78%$185.26M
Blackrock funding, inc. /de5.37M8.07%$170.33M
Blackrock4.69M7.97%$173.61M
Vanguard group4.03M6.06%$109.38M
Fmr3.75M5.64%$118.92M
Point72 asset management3.23M4.86%$102.45M
State street2.80M4.22%$88.95M
Commodore capital lp2.70M4.06%$85.54M
Price t rowe associates inc /md/2.09M3.14%$66.18M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Kynam capital management, lp5.84M11.43%$185.26M
Commodore capital lp2.70M4.95%$85.54M
5am venture management497.27K4.38%$15.77M
Rosalind advisors330.00K4.21%$10.47M
Superstring capital management lp180.05K4.08%$5.71M
Novo1.20M3.08%$38.06M
Eversept partners, lp1.79M2.99%$56.72M
Tsp capital management group375.13K2.90%$11.90M
Propel bio management131.36K2.61%$4.14M
Foresite capital management vi315.91K2.18%$10.02M

Top Buyers

HolderShares% AssetsChange
Point72 asset management3.23M0.13%1.47M
Wellington management group llp8.56M0.05%480.87K
Ikarian capital461.25K1.19%461.25K
Vanguard fiduciary trust429.60K0.00%429.60K
Dimensional fund advisors lp1.06M0.01%407.82K

Top Sellers

HolderShares% AssetsChange
Bellevue group1.20M0.91%-2.42M
T. rowe price investment management---1.70M
Jennison associates---1.32M
Fmr3.75M0.01%-1.16M
Polar capital---1.01M

New Positions

HolderShares% AssetsChangeValue
Ikarian capital461.25K1.19%461.25K$14.63M
Vanguard fiduciary trust429.60K0.00%429.60K$13.63M
Kennedy capital management352.30K0.24%352.30K$11.18M
Rosalind advisors330.00K4.21%330.00K$10.47M
Foresite capital management vi315.91K2.18%315.91K$10.02M

Sold Out

HolderChange
Umb bank, n.a.-2.00
Strategic investment solutions, inc. /il-5.00
Concord wealth partners-8.00
Nelson, van denburg & campbell wealth management group-10.00
Householder group estate & retirement specialist-11.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202623022.99%72,850,785-0.75%1090.90%12449.40%58-3.33%
Dec 31, 2025112-41.05%27,037,989-61.77%400.36%48-51.02%35-31.37%
Sep 30, 20251802.27%69,405,041-0.96%1040.94%95-14.41%5031.58%
Jun 30, 20251843.95%72,686,2280.53%1090.92%11325.56%41-22.64%
Mar 31, 2025180-5.76%73,628,401-0.08%1100.90%90-11.76%5510.00%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Health Care Inv4.28M5.45%29.83K
BB Biotech AG Ord3.56M5.34%250.10K
Vanguard Total Stock Mkt Idx Inv2.45M3.13%304.78K
Vanguard US Total Market Shares ETF2.07M3.11%2.12K
iShares Russell 2000 ETF1.78M2.26%14.99K
Polar Capital Healthcare Opports Inc1.15M1.73%-
State Street® SPDR® S&P® Biotech ETF1.35M1.72%-13.47K
Eventide Healthcare & Life Sciences I1.04M1.56%-319.19K
Polar Capital Biotech S Inc950.00K1.43%-
Vanguard Explorer Inv1.06M1.35%-

Recent Insider Transactions


DateNameRoleActivityValue
Dec 04, 2025Jimenez Freddy A. SVP & GENERAL COUNSELSell$121.21K
Nov 13, 2025Wright Richard M. Former OfficerSell$1.18M
Aug 13, 2025Jimenez Freddy A. SVP & GENERAL COUNSELSell$8.17K
Aug 13, 2025Jimenez Freddy A. SVP & GENERAL COUNSELSell$10.93K
Nov 11, 2024Marucci Anthony S PRESIDENT & CEOBuy$308.43K

Insider Transactions Trends


DateBuySell
2025 Q4-2
2025 Q3-2
2025 Q2--
2024 Q41-
2024 Q2-12

CLDX Ownership FAQ


Who Owns Celldex Therapeutics?

Celldex Therapeutics shareholders are primarily institutional investors at 109.55%, followed by 0.27% insiders and -9.82% retail investors. The average institutional ownership in Celldex Therapeutics's industry, Biotech Stocks , is 35.75%, which Celldex Therapeutics exceeds.

Who owns the most shares of Celldex Therapeutics?

Celldex Therapeutics’s largest shareholders are Wellington management group llp (8.56M shares, 12.87%), Kynam capital management, lp (5.84M shares, 8.78%), and Blackrock funding, inc. /de (5.37M shares, 8.07%). Together, they hold 29.73% of Celldex Therapeutics’s total shares outstanding.

Does Blackrock own Celldex Therapeutics?

Yes, BlackRock owns 7.97% of Celldex Therapeutics, totaling 4.69M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 173.61M$. In the last quarter, BlackRock increased its holdings by 178.84K shares, a 3.96% change.

Who is Celldex Therapeutics’s biggest shareholder by percentage of total assets invested?

Kynam capital management, lp is Celldex Therapeutics’s biggest shareholder by percentage of total assets invested, with 11.43% of its assets in 5.84M Celldex Therapeutics shares, valued at 185.26M$.

Who is the top mutual fund holder of Celldex Therapeutics shares?

Vanguard Health Care Inv is the top mutual fund holder of Celldex Therapeutics shares, with 5.45% of its total shares outstanding invested in 4.28M Celldex Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools